Hims & Hers Shakes Up Weight Loss Market with $49 Pill, Pressuring Pharma Giants

San Francisco, Thursday, 5 February 2026.
Hims & Hers disrupted the sector today by launching a $49 compounded oral semaglutide option, causing Novo Nordisk shares to drop 7% while offering a significantly cheaper alternative to Wegovy.